Athersys, Inc. (ATHX) Trading Up 6.3%
Athersys, Inc. (NASDAQ:ATHX) was up 6.3% during mid-day trading on Tuesday . The stock traded as high as $1.90 and last traded at $1.86. Approximately 1,387,674 shares traded hands during trading, an increase of 107% from the average daily volume of 671,245 shares. The stock had previously closed at $1.75.
Several equities research analysts recently issued reports on ATHX shares. Maxim Group reaffirmed a “buy” rating on shares of Athersys in a research note on Wednesday, May 10th. Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd.
The stock has a 50 day moving average of $1.61 and a 200-day moving average of $1.47. The stock’s market cap is $211.87 million.
Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.96 million. During the same period in the prior year, the company posted ($0.08) EPS. The company’s revenue was up 12.4% compared to the same quarter last year. On average, analysts expect that Athersys, Inc. will post ($0.24) earnings per share for the current fiscal year.
In other Athersys news, EVP John J. Harrington sold 36,000 shares of the company’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $1.45, for a total transaction of $52,200.00. Following the transaction, the executive vice president now directly owns 712,743 shares in the company, valued at approximately $1,033,477.35. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.40% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its position in Athersys by 345.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 68,680 shares during the period. State Street Corp lifted its position in Athersys by 27.2% during the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after purchasing an additional 305,944 shares during the period. Royal Bank of Canada lifted its position in Athersys by 7,334.0% during the 2nd quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 375,723 shares during the period. Vanguard Group Inc. lifted its position in Athersys by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after purchasing an additional 366,572 shares during the period. Finally, Northern Trust Corp lifted its position in Athersys by 30.8% during the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 264,549 shares during the period. Institutional investors own 19.08% of the company’s stock.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.